Last 12 months
Inside the activity.
0 purchase rows · 145 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 9 |
| Dec 2025 | 0 | 8 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 41 |
| Apr 2026 | 0 | 26 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 11 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 18 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 4,684 | $57.54 | $269,517.36 |
DisclosureSEC source: 0001209191-21-017307 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,316 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.95 to 57.93, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.55 | $98,250.00 |
DisclosureSEC source: 0001209191-21-017307 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC |
Pellini Michael JDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-017304 · doc4.xml · derivative · entry 3 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 20,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on February 7, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC |
Pellini Michael JDirector
|
SaleCommon Stock | 20,000 | $57.80 | $1,156,000.00 |
DisclosureSEC source: 0001209191-21-017304 · doc4.xml · nonDerivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.75 to 58.19, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC |
Pellini Michael JDirector
|
Exercise / conversionCommon Stock | 20,000 | $6.55 | $131,000.00 |
DisclosureSEC source: 0001209191-21-017304 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,563 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001209191-21-017305 · doc4.xml · derivative · entry 8 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,375 Underlying: Common Stock · 1,563 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,604 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-017305 · doc4.xml · derivative · entry 7 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,480 Underlying: Common Stock · 2,604 shares Expires 2028-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on October 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,604 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-017305 · doc4.xml · derivative · entry 6 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,834 Underlying: Common Stock · 2,604 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 561 | $58.17 | $32,633.37 |
DisclosureSEC source: 0001209191-21-017305 · doc4.xml · nonDerivative · entry 5 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.115 to 58.27, inclusive. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 6,210 | $57.57 | $357,509.70 |
DisclosureSEC source: 0001209191-21-017305 · doc4.xml · nonDerivative · entry 4 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.95 to 57.93, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 1,563 | $7.27 | $11,363.01 |
DisclosureSEC source: 0001209191-21-017305 · doc4.xml · nonDerivative · entry 3 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,771 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 2,604 | $6.55 | $17,056.20 |
DisclosureSEC source: 0001209191-21-017305 · doc4.xml · nonDerivative · entry 2 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 2,604 | $6.55 | $17,056.20 |
DisclosureSEC source: 0001209191-21-017305 · doc4.xml · nonDerivative · entry 1 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| March 01, 2021 Filed Mar 11, 2021 00:00 UTC Amendment |
Pellini Michael JDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-019622 · doc4a.xml · derivative · entry 3 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 20,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on February 7, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 01, 2021 Filed Mar 11, 2021 00:00 UTC Amendment |
Pellini Michael JDirector
|
SaleCommon Stock | 20,000 | $57.80 | $1,156,000.00 |
DisclosureSEC source: 0001209191-21-019622 · doc4a.xml · nonDerivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 F1 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.75 to 58.19, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 01, 2021 Filed Mar 11, 2021 00:00 UTC Amendment |
Pellini Michael JDirector
|
Exercise / conversionCommon Stock | 20,000 | $6.55 | $131,000.00 |
DisclosureSEC source: 0001209191-21-019622 · doc4a.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2021 Filed Mar 1, 2021 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,771 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-015471 · doc4.xml · derivative · entry 7 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,021 Underlying: Common Stock · 1,771 shares Expires 2028-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 26, 2021 Filed Mar 1, 2021 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,041 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-015471 · doc4.xml · derivative · entry 6 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,084 Underlying: Common Stock · 1,041 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 26, 2021 Filed Mar 1, 2021 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 1,333 | $56.40 | $75,181.20 |
DisclosureSEC source: 0001209191-21-015471 · doc4.xml · nonDerivative · entry 5 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.01 to 56.66, inclusive. Read SEC document |
| February 26, 2021 Filed Mar 1, 2021 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 400 | $55.46 | $22,184.00 |
DisclosureSEC source: 0001209191-21-015471 · doc4.xml · nonDerivative · entry 4 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,633 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.025 to 55.66, inclusive. Read SEC document |
| February 26, 2021 Filed Mar 1, 2021 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 1,079 | $54.47 | $58,773.13 |
DisclosureSEC source: 0001209191-21-015471 · doc4.xml · nonDerivative · entry 3 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,033 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $54.00 to 54.855, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 26, 2021 Filed Mar 1, 2021 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 1,771 | $6.55 | $11,600.05 |
DisclosureSEC source: 0001209191-21-015471 · doc4.xml · nonDerivative · entry 2 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. Read SEC document |
| February 26, 2021 Filed Mar 1, 2021 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 1,041 | $7.80 | $8,119.80 |
DisclosureSEC source: 0001209191-21-015471 · doc4.xml · nonDerivative · entry 1 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-015501 · doc4.xml · derivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,325 Underlying: Common Stock · 15,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 15,000 | $56.23 | $843,450.00 |
DisclosureSEC source: 0001209191-21-015501 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.01 to 56.66, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.55 | $98,250.00 |
DisclosureSEC source: 0001209191-21-015501 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 23:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 14,675 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-014920 · doc4.xml · derivative · entry 10 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,325 Underlying: Common Stock · 14,675 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F8 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 23:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 599 | $57.33 | $34,340.67 |
DisclosureSEC source: 0001209191-21-014920 · doc4.xml · nonDerivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.00 to 57.63, inclusive. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 23:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 14,076 | $56.13 | $790,085.88 |
DisclosureSEC source: 0001209191-21-014920 · doc4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 599 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.00 to 56.80, inclusive. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 23:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 14,675 | $6.55 | $96,121.25 |
DisclosureSEC source: 0001209191-21-014920 · doc4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 23:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-014920 · doc4.xml · derivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 15,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F8 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 23:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 3,258 | $59.33 | $193,297.14 |
DisclosureSEC source: 0001209191-21-014920 · doc4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.24 to 59.415, inclusive. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 23:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 3,374 | $58.74 | $198,188.76 |
DisclosureSEC source: 0001209191-21-014920 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,258 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.20 to 59.13, inclusive. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 23:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 4,134 | $57.12 | $236,134.08 |
DisclosureSEC source: 0001209191-21-014920 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,632 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.00 to 57.91, inclusive. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 23:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 4,234 | $56.45 | $239,009.30 |
DisclosureSEC source: 0001209191-21-014920 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,766 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.12 to 56.97, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 23:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.55 | $98,250.00 |
DisclosureSEC source: 0001209191-21-014920 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-014088 · doc4.xml · derivative · entry 11 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,000 Underlying: Common Stock · 15,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F9 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 7,039 | $56.04 | $394,465.56 |
DisclosureSEC source: 0001209191-21-014088 · doc4.xml · nonDerivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F8 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.00 to 56.19, inclusive. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 4,461 | $55.54 | $247,763.94 |
DisclosureSEC source: 0001209191-21-014088 · doc4.xml · nonDerivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,039 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.03 to 55.99, inclusive. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 3,500 | $54.16 | $189,560.00 |
DisclosureSEC source: 0001209191-21-014088 · doc4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $54.025 to 54.75, inclusive. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.55 | $98,250.00 |
DisclosureSEC source: 0001209191-21-014088 · doc4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-014088 · doc4.xml · derivative · entry 10 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 15,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F9 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 656 | $62.20 | $40,803.20 |
DisclosureSEC source: 0001209191-21-014088 · doc4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $61.81 to 62.34, inclusive. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 400 | $61.01 | $24,404.00 |
DisclosureSEC source: 0001209191-21-014088 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 656 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $60.70 to 61.21, inclusive. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 4,100 | $60.21 | $246,861.00 |
DisclosureSEC source: 0001209191-21-014088 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,056 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.695 to 60.67, inclusive. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 9,844 | $59.28 | $583,552.32 |
DisclosureSEC source: 0001209191-21-014088 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,156 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.69 to 59.65, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.55 | $98,250.00 |
DisclosureSEC source: 0001209191-21-014088 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-012906 · doc4.xml · derivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,000 Underlying: Common Stock · 15,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 3,793 | $63.03 | $239,072.79 |
DisclosureSEC source: 0001209191-21-012906 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $62.87 to 63.12, inclusive. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 7,708 | $62.30 | $480,208.40 |
DisclosureSEC source: 0001209191-21-012906 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,793 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $61.86 to 62.855, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.